BACKGROUND: Patients with localized gastric adenocarcinoma (LGAC), who get pre-operative therapy, have heterogeneous/unpredictable outcomes. Predictive clinical variables/biomarkers are not established. METHODS: We analyzed 107 LGAC patients who had chemoradiation and surgery. LGACs were grouped for (1) presence/absence of signet ring cell histology (SRC) and (2) histologic grade: G2 or G3. %SRC was assessed (0, 1-10, 11-49, and 50-100%) and correlated with pathologic complete response (pathCR) or <pathCR in the resected specimens. RESULTS: Most patients were men (60%), had stage cIII LGAC (50%), and received chemotherapy before chemoradiation (93%). Most had G3 tumors (78%) and SRC (58%). Presence of SRC was associated with a lower rate of pathCR (11 vs. 36%, p = 0.004), and the association remained significant even with a low percentage of SRC (1-10%; p = 0.014). The higher the fraction of SRC, the lower was the probability of pathCR (p = 0.03). G3 and SRC led to a shorter overall survival (OS) (p = 0.046 and p = 0.038, respectively). yp stage independently prognosticated OS and recurrence-free survival (p < 0.001). CONCLUSION: Our novel findings suggest that LGACs with SRC are relatively chemoradiation resistant compared to LGACs without SRC. A higher fraction of SRC is associated with higher resistance. Upon validation/biomarker(s) evaluation, reporting of the fraction of SRC may be warranted.
BACKGROUND:Patients with localized gastric adenocarcinoma (LGAC), who get pre-operative therapy, have heterogeneous/unpredictable outcomes. Predictive clinical variables/biomarkers are not established. METHODS: We analyzed 107 LGAC patients who had chemoradiation and surgery. LGACs were grouped for (1) presence/absence of signet ring cell histology (SRC) and (2) histologic grade: G2 or G3. %SRC was assessed (0, 1-10, 11-49, and 50-100%) and correlated with pathologic complete response (pathCR) or <pathCR in the resected specimens. RESULTS: Most patients were men (60%), had stage cIII LGAC (50%), and received chemotherapy before chemoradiation (93%). Most had G3 tumors (78%) and SRC (58%). Presence of SRC was associated with a lower rate of pathCR (11 vs. 36%, p = 0.004), and the association remained significant even with a low percentage of SRC (1-10%; p = 0.014). The higher the fraction of SRC, the lower was the probability of pathCR (p = 0.03). G3 and SRC led to a shorter overall survival (OS) (p = 0.046 and p = 0.038, respectively). yp stage independently prognosticated OS and recurrence-free survival (p < 0.001). CONCLUSION: Our novel findings suggest that LGACs with SRC are relatively chemoradiation resistant compared to LGACs without SRC. A higher fraction of SRC is associated with higher resistance. Upon validation/biomarker(s) evaluation, reporting of the fraction of SRC may be warranted.
Authors: Tsung-Teh Wu; Lucian R Chirieac; Susan C Abraham; Alyssa M Krasinskas; Huamin Wang; Asif Rashid; Arlene M Correa; Wayne L Hofstetter; Jaffer A Ajani; Stephen G Swisher Journal: Am J Surg Pathol Date: 2007-01 Impact factor: 6.394
Authors: Jaffer A Ajani; Kathryn Winter; Gordon S Okawara; John H Donohue; Peter W T Pisters; Christopher H Crane; John F Greskovich; P Rani Anne; Jeffrey D Bradley; Christopher Willett; Tyvin A Rich Journal: J Clin Oncol Date: 2006-08-20 Impact factor: 44.544
Authors: Viren R Patel; Wayne L Hofstetter; Arlene M Correa; Atin Agarwal; Asif Rashid; Manoop S Bhutani; Steven H Lin; Jaffer A Ajani; Stephen G Swisher; Dipen M Maru Journal: Ann Thorac Surg Date: 2014-07-16 Impact factor: 4.330
Authors: Michael Stahl; Martin K Walz; Martin Stuschke; Nils Lehmann; Hans-Joachim Meyer; Jorge Riera-Knorrenschild; Peter Langer; Rita Engenhart-Cabillic; Michael Bitzer; Alfred Königsrainer; Wilfried Budach; Hansjochen Wilke Journal: J Clin Oncol Date: 2009-01-12 Impact factor: 44.544
Authors: Stephen R Smalley; Jacqueline K Benedetti; Daniel G Haller; Scott A Hundahl; Norman C Estes; Jaffer A Ajani; Leonard L Gunderson; Bryan Goldman; James A Martenson; J Milburn Jessup; Grant N Stemmermann; Charles D Blanke; John S Macdonald Journal: J Clin Oncol Date: 2012-05-14 Impact factor: 44.544
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396
Authors: Kazuto Harada; Madhavi Patnana; Xuemei Wang; Masaaki Iwatsuki; Mariela A Blum Murphy; Meina Zhao; Prajnan Das; Bruce D Minsky; Brian Weston; Jeffrey H Lee; Manoop S Bhutani; Jeannelyn S Estrella; Namita Shanbhag; Naruhiko Ikoma; Brian D Badgwell; Jaffer A Ajani Journal: Surg Today Date: 2020-05-14 Impact factor: 2.540
Authors: Lei Huang; Lina Jansen; Rob H A Verhoeven; Jelle P Ruurda; Liesbet Van Eycken; Harlinde De Schutter; Jan Johansson; Mats Lindblad; Tom B Johannesen; Vesna Zadnik; Tina Žagar; Margit Mägi; Sjoerd M Lagarde; Esther Bastiaannet; Cornelis J H van de Velde; Petra Schrotz-King; Hermann Brenner Journal: Ther Adv Med Oncol Date: 2021-06-28 Impact factor: 8.168
Authors: K G P Kerckhoffs; D H W Liu; L Saragoni; R S van der Post; R Langer; M Bencivenga; M Iglesias; G Gallo; L C Hewitt; G E Fazzi; A M Vos; F Renaud; T Yoshikawa; T Oshima; A Tomezzoli; G de Manzoni; T Arai; R Kushima; F Carneiro; H I Grabsch Journal: Gastric Cancer Date: 2020-06-02 Impact factor: 7.370